Skip to content
Study details
Enrolling now

A Study of Suvorexant for Insomnia in People with Opioid Use Disorder

Merck Sharp & Dohme LLC
NCT IDNCT06655883ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

300

Study length

about 1.7 years

Ages

18–70

Locations

10 sites in CT, GA, MD +6

About this study

This trial is testing if suvorexant, a medication, helps people with opioid use disorder (OUD) sleep better. Researchers are also looking at how safe and well-tolerated suvorexant is compared to a placebo.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Placebo
  • 2.Take Suvorexant
PhasePhase 3
DrugSuvorexant
Routeoral
Primary goalChange from Baseline in Total Sleep Time at Week 8

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low5%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

suvorexant

Drug routes

oral (Oral Tablet)

Endpoints

Primary: Change from Baseline in Total Sleep Time at Week 8, Number of Participants Who Discontinue Study Treatment Due to an AE, Number of Participants Who Experience One or More Adverse Events (AEs), Number of Participants Who Experience One or More Serious Adverse Events (SAEs)

Secondary: Change from Baseline in Wakefulness after Persistent Sleep Onset at Week 8